CG Oncology, Inc. Common stock (CGON) — Defensive Interval Ratio
CG Oncology, Inc. Common stock (CGON) has a Defensive Interval Ratio of 8408 days as of December 2025. Defensive assets of $710.35 Million (cash $-, short-term investments $709.66 Million, receivables $688.00K) cover 8408 days of daily cash needs of $84.48K/day. See CGON current assets to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Defensive Interval Ratio
Defensive Assets
Daily Cash Need
Current Liabilities
CG Oncology, Inc. Common stock Defensive Interval Ratio (2021–2025)
This chart shows how CG Oncology, Inc. Common stock's Defensive Interval Ratio has evolved across 5 annual periods from 2021 to 2025. As of December 2025, the ratio stands at 8408 days, meaning defensive assets of $710.35 Million can fund 8408 days of operations without new revenue. See CG Oncology, Inc. Common stock balance sheet quality to measure how much of total assets are equity-financed.
Annual Defensive Interval Ratio for CG Oncology, Inc. Common stock (2021–2025)
The table below presents the year-by-year Defensive Interval Ratio for CG Oncology, Inc. Common stock from 2021 to 2025, covering 5 annual filings. Each row shows defensive assets, daily cash need, the DIR in days, and the change in days compared to the prior year. For live market cap and the full company financial profile, see CG Oncology, Inc. Common stock (CGON) market capitalisation.
| Year | DIR (days) | Defensive Assets (USD) | Daily Cash Need | Cash | ST Investments | Change (days) |
|---|---|---|---|---|---|---|
| 2025 | 8408 days | $710.35 Million | $84.48K/day | $- | $709.66 Million | ▲ +112 days |
| 2024 | 8297 days | $485.71 Million | $58.54K/day | $- | $484.93 Million | ▲ +3700 days |
| 2023 | 4596 days | $179.50 Million | $39.05K/day | $- | $179.41 Million | ▲ +3280 days |
| 2022 | 1316 days | $55.64 Million | $42.27K/day | $- | $55.34 Million | ▲ +1316 days |
| 2021 | 0 days | $2.00K | $16.37K/day | $- | $0.00 | — |